5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Bliss GVS Pharma Ltd.

•
blissgvs.comBSE: 506197NSE: BLISSGVS
Market Cap₹ 7,682 Cr.
Current Price
High / Low₹ 726 / 118
Stock P/E67.1
Book Value₹ 111
Price to Book1.99
Dividend Yield0.21 %
ROCE12.8 %
ROE8.8 %
Face Value₹ 1

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Latest quarter profit grew 83.5% YoY, showing strong momentum
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.40x)
  • Company generates healthy free cash flow
  • Company has a consistent dividend-paying track record

CONS

  • A large part of profit comes from other income (43.8% of PBT)
  • Company has a low return on equity of 7.0% over last 3 years
  • Company has a low return on capital employed of 9.8%
  • Valuation is stretched - P/E of 67.1 is well above its own 5-year median (23.3)
  • Operating margins have contracted to 15.4% from 23.6%
  • Company has delivered a poor profit growth of 7.5% over past five years

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.BLISSGVS722.4556.417681.840.2151.3715.80285.5837.6517.4026.75
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
109171161164149183180156163190165212222
98129133139122159154142131172138167179
Operating Profit11422925272426143318274442
OPM %10.14%24.70%17.76%15.35%17.95%12.94%14.33%8.80%20.05%9.47%16.30%20.87%19.16%
7118-3371012911268109
Interest1122131153120
Depreciation5666667788889
Profit before Tax114629-15262430143133254451
Tax %31.26%26.44%27.35%24.75%25.74%28.67%29.29%20.26%31.12%25.88%26.41%26.57%24.59%
Net Profit83421-11191721112125193239
0.723.251.99-1.111.851.632.001.082.002.351.763.063.65

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
348298427442466636598605667730788
247209333342374527508498576611657
Operating Profit1018893100911099010792119131
OPM %28.89%29.70%21.82%22.66%19.65%17.16%15.07%17.70%13.73%16.34%16.68%
9113637193551-8365652
Interest9737641067116
Depreciation666914141524273132
Profit before Tax9587120122911261167094133154
Tax %37.69%34.34%37.98%24.14%25.98%26.69%26.12%27.92%26.76%27.42%25.74%
Net Profit59577492689385516997114
EPS0.000.000.000.006.408.818.104.846.559.16—
Dividend Payout %10.47%18.09%13.86%5.59%7.64%5.59%6.09%10.34%7.64%16.38%—

COMPOUNDED SALES GROWTH

10 Years:
8%
5 Years:
9%
3 Years:
7%

COMPOUNDED PROFIT GROWTH

10 Years:
4%
5 Years:
7%
3 Years:
4%

STOCK PRICE CAGR

10 Years:
17%
5 Years:
45%
3 Years:
99%
1 Year:
370%

RETURN ON EQUITY

10 Years:
10%
5 Years:
8%
3 Years:
7%
Last Year:
9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Jul 8

₹ 1

Rs.1.0000 per share(100%)Final Dividend

2026

Feb 18

₹ 0.50

Rs.0.5000 per share(50%)Interim Dividend

2025

Jul 24

₹ 0.50

Rs.0.5000 per share(50%)Final Dividend

2024

Jul 18

₹ 0.50

Rs.0.5000 per share(50%)Final Dividend

2023

Jul 12

₹ 0.50

Rs.0.5000 per share(50%)Final Dividend

2022

Jun 20

₹ 0.50

Rs.0.5000 per share(50%)Final Dividend

2021

Sep 13

₹ 0.50

Rs.0.5000 per share(50%)Final Dividend

2020

Sep 17

₹ 0.50

Rs.0.5000 per share(50%)Dividend

2018

Aug 14

₹ 1

Rs.1.0000 per share(100%)Final Dividend

2017

Sep 18

₹ 0.60

Rs.0.6000 per share(60%)Dividend

2016

Sep 6

₹ 0.50

Rs.0.5000 per share(50%)Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital10101010101010101111
4815315936737358319189701,0421,133
74947274916880553617
Trade Payables64353156678476546096
37233042428656566372
Total Liabilities6666947368559461,0801,1401,1461,2111,329
757278179174224325330368420
Capital Work in Progress2043022238214
22191919181818191919
284055618490748982111
0000000400429457
Cash & Bank8470938712014985169171111
456492447510548576635131122208
Total Assets6666947368559461,0801,1401,1461,2111,329

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
7659989590145828297123
Cash from Investing-2916-68-60-62-92-13-66-78-51
Cash from Financing-15-229-6-12-13-26-21-27-75
-617-11-3-695-4-7-4

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
34.9034.8235.1035.2935.4435.3935.3635.3635.01
13.2412.1313.5113.1812.6513.2714.5410.458.07
6.586.566.556.556.545.985.785.049.32
Government0.000.000.000.000.000.000.000.000.00
45.2746.4944.8444.9845.3645.3644.3249.1547.59

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-04
ESOP/ESOS/ESPS

2026-09-04 - Bliss GVS Pharma Limited has informed the Exchange regarding the ESOP Allotment Committee of the Company at its meeting held today i.e. September 04,2026 has approved the allotment of 55,250 equity shares of the face value Re 1/- to the eligible employees who have exercised their stock options under the Bliss GVS Pharma Limited- Employee Stock Option Plan (Bliss GVS ESOP - 2019)

2026-09-02
Updates

2026-09-02 - SBI Capital Markets Ltd has submitted to the Exchange a copy of Post offer advertisement in accordance with Regulation 18(12) of the SEBI (SAST) Regulations, 2011, as amended, for the attention of the public shareholders of the company.

2026-08-25
Copy of Newspaper Publication

2026-08-25 - Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding Extension of Special Window for Re-Lodgement of Transfer Requests of Physical Shares

2026-08-21
Copy of Newspaper Publication

2026-08-21 - Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding the Advertisement of the Postal Ballot Notice.

2026-08-20
Shareholders meeting

2026-08-20 - Bliss GVS Pharma Limited has informed the Exchange regarding Notice of Postal Ballot

2026-08-14
Copy of Newspaper Publication

2026-08-14 - Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding the extract of the statement of un-audited standalone andconsolidated financial results for the quarter ended June 30, 2026.

2026-08-12
General Updates

2026-08-12 - Bliss GVS Pharma Limited has informed the Exchange about General Updates regarding grant of options under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019.

2026-08-12
Outcome of Board Meeting

2026-08-12 - Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026 along with the Limited Review Report and the draft of the Postal Ballot Notice seeking the approval of members of the Company for the appointment of Mr. Santosh Parab (DIN: 01622988) as a Director of the Company in the capacity of Non-Executive Non-Independent Director of the Company.

2026-08-11
Allotment of Securities

2026-08-11 - Bliss GVS Pharma Limited has informed the Exchange regarding allotment of 31250 securities pursuant to ESOP/ESPS at its meeting held on August 11, 2026

News

Recent coverage and analyst commentary for BLISSGVS

Loading news…

🤖

AI Stock Analyst

Bliss GVS Pharma Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login